Adjuvant capecitabine in biliary tract cancer: a standard option?

David Malka; Julien Edeline

doi:10.1016/s1470-2045(19)30022-1

Adjuvant capecitabine in biliary tract cancer: a standard option?

David Malka
, Julien Edeline

Institut Gustave Roussy
Centre Georges-François Leclerc

Research output: Contribution to journal › Comment/debate

31 Scopus citations

Original language	English
Pages (from-to)	606-608
Number of pages	3
Journal	The Lancet Oncology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/s1470-2045(19)30022-1
State	Published - May 2019
Externally published	Yes

Bibliographical note

Funding Information:
DM has received honoraria for lectures from Amgen, Bayer, HalioDx, Merck Serono, Merck Sharpe & Dohme (MSD), Roche, Sanofi, and Servier; honoraria for participation in advisory boards from Agios, Bayer, HalioDx, MSD, Roche, Servier, Shire, and Halio Dx; and travel support from Amgen, Bayer, Merck Serono, MSD, Roche, Sanofi, and Servier. JE reports grants from BTG, and personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Ipsen, and Novartis. He is the coordinating investigator of PRODIGE 12, an adjuvant chemotherapy study in biliary tract cancer, discussed in this comment and the related article.

Funding

DM has received honoraria for lectures from Amgen, Bayer, HalioDx, Merck Serono, Merck Sharpe & Dohme (MSD), Roche, Sanofi, and Servier; honoraria for participation in advisory boards from Agios, Bayer, HalioDx, MSD, Roche, Servier, Shire, and Halio Dx; and travel support from Amgen, Bayer, Merck Serono, MSD, Roche, Sanofi, and Servier. JE reports grants from BTG, and personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Ipsen, and Novartis. He is the coordinating investigator of PRODIGE 12, an adjuvant chemotherapy study in biliary tract cancer, discussed in this comment and the related article.

Funders
Novartis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/s1470-2045(19)30022-1

Cite this

@article{18d94e3ba3e442adb8e98f93398f6ea7,

title = "Adjuvant capecitabine in biliary tract cancer: a standard option?",

author = "David Malka and Julien Edeline",

note = "Funding Information: DM has received honoraria for lectures from Amgen, Bayer, HalioDx, Merck Serono, Merck Sharpe \& Dohme (MSD), Roche, Sanofi, and Servier; honoraria for participation in advisory boards from Agios, Bayer, HalioDx, MSD, Roche, Servier, Shire, and Halio Dx; and travel support from Amgen, Bayer, Merck Serono, MSD, Roche, Sanofi, and Servier. JE reports grants from BTG, and personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Ipsen, and Novartis. He is the coordinating investigator of PRODIGE 12, an adjuvant chemotherapy study in biliary tract cancer, discussed in this comment and the related article.",

year = "2019",

month = may,

doi = "10.1016/s1470-2045(19)30022-1",

language = "אנגלית",

volume = "20",

pages = "606--608",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "5",

}

TY - JOUR

T1 - Adjuvant capecitabine in biliary tract cancer

T2 - a standard option?

AU - Malka, David

AU - Edeline, Julien

N1 - Funding Information: DM has received honoraria for lectures from Amgen, Bayer, HalioDx, Merck Serono, Merck Sharpe & Dohme (MSD), Roche, Sanofi, and Servier; honoraria for participation in advisory boards from Agios, Bayer, HalioDx, MSD, Roche, Servier, Shire, and Halio Dx; and travel support from Amgen, Bayer, Merck Serono, MSD, Roche, Sanofi, and Servier. JE reports grants from BTG, and personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Ipsen, and Novartis. He is the coordinating investigator of PRODIGE 12, an adjuvant chemotherapy study in biliary tract cancer, discussed in this comment and the related article.

PY - 2019/5

Y1 - 2019/5

UR - https://www.scopus.com/pages/publications/85064836395

U2 - 10.1016/s1470-2045(19)30022-1

DO - 10.1016/s1470-2045(19)30022-1

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 30922732

AN - SCOPUS:85064836395

SN - 1470-2045

VL - 20

SP - 606

EP - 608

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 5

ER -

Adjuvant capecitabine in biliary tract cancer: a standard option?

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Cite this